; and (2) the potential benefits of the use of opioid agonists or partial agonists for affected individuals. (b) Report Not later than 1 year after the date of enactment of the STOP Fentanyl Act of 2023 , the Secretary shall submit to the Committee on Health, Education, Labor, and Pensions of the Senate and the Committee on Energy and Commerce of the House of Representatives a report that includes the following data on the education programs funded pursuant to grants under subsection (a): (1) The number of people reached by educational materials funded pursuant to grants under subsection (a). (2) The geographic areas where people received such educational materials. (3) The remaining populations and areas targeted for awareness of such educational materials, including the characteristics of such populations and areas, such as the type of stakeholder. (4) The outcomes of education provided pursuant to grants under subsection (a), as determined by the Secretary. (c) Authorization of appropriations There are authorized to be appropriated to carry out this section such sums as are necessary. . 302. GAO study on naloxone access (a) In general The Comptroller General of the United States shall conduct a study on actions that may be taken to ensure appropriate access and affordability of naloxone for individuals seeking to purchase naloxone. Such study shall address what is known about— (1) coverage of naloxone (in any available form), including whether naloxone can be covered as an over-the-counter drug under a group health plan or group or individual health insurance coverage (as such terms are defined in section 2791 of the Public Health Service Act ( 42 U.S.C. 300gg–91 )) or for individuals entitled to benefits under part A or enrolled under part B of title XVIII of the Social Security Act ( 42 U.S.C. 1395 et seq. ), or receiving medical assistance under a State plan under title XIX of such Act ( 42 U.S.C. 1396 et seq. ) or a waiver of such plan